Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company.
The United States agreed to buy 600,000 more doses of GSK and Vir Biotechnology’s COVID-19 antibody therapy for an undisclosed sum, as the country bolsters its arsenal of treatments against the Omicron coronavirus variant.
Ex-GlaxoSmithKline researcher Lucy Xi pled guilty to conspiracy to steal trade secrets from her former company to help a rival firm launch a business in China.
Sanofi and GlaxoSmithKline said on December 15 they expect data from late-stage clinical trials of the booster dose of their COVID-19 vaccine candidate in first-quarter 2022, instead of this year, another delay for the potential shot.
GSK said on December 7 the British drugmaker’s antibody-based Covid-19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.
Laboratory analysis of the antibody-based Covid-19 therapy GlaxoSmithKline is developing with U.S. partner Vir Biotechnology indicated the drug is effective against the new Omicron variant, the British drugmaker said on December 2.
GSK hired one of the scientists behind Pfizer’s mRNA COVID-19 shot, Phil Dormitzer, as the company’s global head of R&D for vaccines and he will join the British drugmaker from Dec. 3.
The United States signed contracts worth about $1 billion for doses of the antibody-based Covid-19 treatment from Britain’s GSK and U.S.-based Vir Biotechnology, as countries seek to secure promising options beyond vaccines.
Britain’s GSK and partner Vir Biotechnology said on November 12 their antibody-based Covid-19 drug was shown in a trial to work as well when given as a shot in the arm as when administered via the standard infusion, potentially offering more convenience.
GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study that showed the investigational candidate daprodustat improved or maintained hemoglobin levels without an increase in cardiovascular risk.
